Patient guide · Reviewed June 2026
Why Half of GLP-1 Patients Stop Within a Year — and What Actually Helps You Stay the Course
If you're starting or considering a GLP-1 medication, it's worth knowing upfront: a large share of people who start these medications don't stay on them for long. Understanding why — and what's actually been shown to improve the odds — is some of the most practically useful information available before you begin.
Published 2026-06-01 · Clinically reviewed 2026-06-03
Patient guide · Reviewed June 2026
The discontinuation numbers
Real-world data tells a different story to the headline efficacy figures from clinical trials. Pharmacoeconomic analyses indicate that approximately 50% of…
Real-world data tells a different story to the headline efficacy figures from clinical trials. Pharmacoeconomic analyses indicate that approximately 50% of patients discontinue GLP-1 therapy within the first year of starting.
The picture varies considerably depending on why someone is taking the medication. A large-scale observational study of 96,544 patients initiating GLP-1 receptor agonists found that one-year discontinuation was significantly higher among patients without type 2 diabetes (65%) than those with type 2 diabetes (46%). In other words, people using these medications purely for weight management were considerably more likely to stop than people using them to manage diabetes.
The pattern continues after stopping, too: patients who used a GLP-1 solely for weight management were also significantly less likely to restart therapy within a year if they did stop (35%), compared with patients managing diabetes (51%).
The good news: persistence has improved substantially
While the discontinuation rate remains high, the trend is moving in a meaningfully positive direction. One-year persistence rates for high-potency, weight-loss-indicated GLP-1 medications nearly doubled, rising from 33% in 2021 to 61% in the first half of 2024. This improvement is primarily attributed to two factors: resolved manufacturing shortages (which previously forced many patients to stop simply because medication wasn't available) and more structured clinical support systems becoming more widely available.
Patient guide · Reviewed June 2026
Why people actually stop
The research identifies several consistent drivers of discontinuation:
The research identifies several consistent drivers of discontinuation:
- Acute gastrointestinal side effects — severe nausea, vomiting, and diarrhoea, particularly during dose escalation
- High out-of-pocket costs — a significant factor given most GLP-1 use in Australia for weight management sits outside PBS subsidy
- Inconsistent supply — less of an issue now than during the 2022–2023 shortage period, but still a factor for some patients and medications
The finding that matters most: how you're managed affects whether you stick with it
Here's the detail with the most practical relevance if you're deciding how to start GLP-1 therapy: real-world cohort analyses reveal that patients managed within structured, specialist-led, or multidisciplinary care programs exhibit significantly higher persistence than those prescribed medications through transactional GP consultations alone.
The mechanisms behind this aren't mysterious — they're exactly the kind of support that helps manage the predictable, dose-related challenges of GLP-1 therapy:
- Continuous clinical monitoring to track progress and catch problems early
- Proactive side-effect management — adjusting titration pace, timing, or supportive measures before gastrointestinal side effects become severe enough to cause someone to quit
- Digital check-ins that catch early signs of struggle before they become a reason to stop
- Integrated lifestyle coaching — particularly nutrition support, which helps patients navigate the early adjustment period
This combination helps patients navigate the early tolerability issues that are the single biggest reason people stop in the first place, reducing premature discontinuation.
Patient guide · Reviewed June 2026
Why stopping matters beyond just losing access to the medication
If you do stop, it's worth understanding what tends to happen next: weight regain of approximately 10 kg typically occurs within 12 to 18 months of stopping…
If you do stop, it's worth understanding what tends to happen next: weight regain of approximately 10 kg typically occurs within 12 to 18 months of stopping therapy. This isn't because the medication "stops working" after you quit — it reflects the fact that GLP-1 medications manage appetite and metabolic signalling actively, and that effect recedes once the medication is no longer in your system, similarly to how blood pressure tends to rise again if you stop an effective blood pressure medication.
This is precisely why the structure of your care matters as much as the medication itself: a patient who's supported through the difficult early months, with side effects actively managed and progress monitored, is considerably more likely to still be benefiting from treatment a year later than someone managing it alone through occasional check-ins.
What this means if you're starting GLP-1 therapy
- Ask what support is built into your specific prescribing pathway before you start — is it a single consultation and a script, or does it include structured follow-up, side-effect management, and nutrition support?
- Expect the first weeks to be the hardest, and know that gastrointestinal side effects during this period are the most common reason people stop — having a plan to manage this in advance matters
- Factor in the realistic ongoing cost before starting, given cost is one of the most common reasons people discontinue
- If you're not getting structured follow-up, ask for it or consider whether a more multidisciplinary care pathway — involving a dietitian, regular monitoring, or specialist input — would suit you better than a purely transactional prescribing model
If part of your reason for researching a clinic or specialist is to find genuinely structured, ongoing support rather than a one-off prescription, that's a well-evidenced reason to prioritise — not just a nice-to-have.
Find a liver elastography clinic near you
Search by suburb or postcode to see accredited clinics offering FibroScan and guided liver elastography across Australia.
Type a suburb or postcode and press Enter to search nearby.
Request a liver scan appointment
Submit your details and we'll route your request to the most appropriate elastography clinic in your area. Most clinics respond within 1–2 business days.
Take action
Request an appointment
Frequently asked questions
Why do people stop taking Ozempic or Wegovy?
The main reasons are gastrointestinal side effects during dose escalation, high out-of-pocket cost, and historically supply shortages. Roughly 50% discontinue within the first year.
What happens when you stop GLP-1 medication?
Appetite typically returns and weight regain of around 10 kg within 12–18 months is common without ongoing lifestyle support.
Does monitored care help you stay on GLP-1 longer?
Yes. Structured, multidisciplinary care programs show significantly higher persistence than transactional prescribing alone.
Are discontinuation rates improving in Australia?
One-year persistence for weight-loss GLP-1s rose from 33% in 2021 to 61% in early 2024, partly due to better supply and more structured support.
Pharmacoeconomic real-world persistence analyses of GLP-1 receptor agonist therapy, 2021–2024; observational cohort study of 96,544 patients initiating GLP-1 receptor agonist therapy, comparing discontinuation by diabetes status; published research on weight regain trajectories following GLP-1 discontinuation.
This article is for educational purposes only. It does not constitute medical advice. Always consult your GP or a specialist about your individual health circumstances.
Next step
Find a liver elastography clinic near you
Search participating clinics across Australia, or talk to your GP about a baseline FIB-4 and elastography.